Ron Carico1, Xinhua Zhao1, Carolyn T Thorpe2, Joshua M Thorpe2, Florentina E Sileanu1, John P Cashy1, Jennifer A Hale1, Maria K Mor3, Thomas R Radomski4, Leslie R M Hausmann4, Julie M Donohue3, Katie J Suda5, Kevin Stroupe6, Joseph T Hanlon7, Chester B Good8, Michael J Fine4, Walid F Gellad4. 1. VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania (R.C., X.Z., F.E.S., J.P.C., J.A.H.). 2. VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, and University of North Carolina School of Pharmacy, Chapel Hill, North Carolina (C.T.T., J.M.T.). 3. VA Pittsburgh Healthcare System and University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania (M.K.M., J.M.D.). 4. VA Pittsburgh Healthcare System and University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (T.R.R., L.R.H., M.J.F., W.F.G.). 5. University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania; Edward Hines, Jr. VA Hospital and University of Illinois at Chicago College of Pharmacy, Chicago, Illinois (K.J.S.). 6. Edward Hines, Jr. VA Hospital, Chicago, Illinois (K.S.). 7. VA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, and University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania (J.T.H.). 8. VA Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, and UPMC Health Plan, Pittsburgh, Pennsylvania (C.B.G.).
Abstract
Background: Overlapping use of opioids and benzodiazepines is associated with increased risk for overdose. Veterans receiving medications concurrently from the U.S. Department of Veterans Affairs (VA) and Medicare may be at higher risk for such overlap. Objective: To assess the association between dual use of VA and Medicare drug benefits and receipt of overlapping opioid and benzodiazepine prescriptions. Design: Cross-sectional. Setting: VA and Medicare. Participants: All veterans enrolled in VA and Medicare Part D who filled at least 2 opioid prescriptions in 2013 (n = 368 891). Measurements: Outcomes were the proportion of patients with a Pharmacy Quality Alliance (PQA) measure of opioid-benzodiazepine overlap (≥2 filled prescriptions for benzodiazepines with ≥30 days of overlap with opioids) and the proportion of patients with high-dose opioid-benzodiazepine overlap (≥30 days of overlap with a daily opioid dose >120 morphine milligram equivalents). Augmented inverse probability weighting regression was used to compare these measures by prescription drug source: VA only, Medicare only, or VA and Medicare (dual use). Results: Of 368 891 eligible veterans, 18.3% received prescriptions from the VA only, 30.3% from Medicare only, and 51.4% from both VA and Medicare. The proportion with PQA opioid-benzodiazepine overlap was larger for the dual-use group than the VA-only group (23.1% vs. 17.3%; adjusted risk ratio [aRR], 1.27 [95% CI, 1.24 to 1.30]) and Medicare-only group (23.1% vs. 16.5%; aRR, 1.12 [CI, 1.10 to 1.14]). The proportion with high-dose overlap was also larger for the dual-use group than the VA-only group (4.7% vs. 2.3%; aRR, 2.23 [CI, 2.10 to 2.36]) and Medicare-only group (4.7% vs. 2.9%; aRR, 1.06 [CI, 1.02 to 1.11]). Limitation: Data are from 2013 and cannot capture medications purchased without insurance; unmeasured confounding may remain in this cross-sectional study. Conclusion: Among a national cohort of veterans dually enrolled in VA and Medicare, receiving prescriptions from both sources was associated with greater risk for receiving potentially unsafe overlapping prescriptions for opioids and benzodiazepines. Primary Funding Source: U.S. Department of Veterans Affairs.
Background: Overlapping use of opioids and benzodiazepines is associated with increased risk for overdose. Veterans receiving medications concurrently from the U.S. Department of Veterans Affairs (VA) and Medicare may be at higher risk for such overlap. Objective: To assess the association between dual use of VA and Medicare drug benefits and receipt of overlapping opioid and benzodiazepine prescriptions. Design: Cross-sectional. Setting: VA and Medicare. Participants: All veterans enrolled in VA and Medicare Part D who filled at least 2 opioid prescriptions in 2013 (n = 368 891). Measurements: Outcomes were the proportion of patients with a Pharmacy Quality Alliance (PQA) measure of opioid-benzodiazepine overlap (≥2 filled prescriptions for benzodiazepines with ≥30 days of overlap with opioids) and the proportion of patients with high-dose opioid-benzodiazepine overlap (≥30 days of overlap with a daily opioid dose >120 morphine milligram equivalents). Augmented inverse probability weighting regression was used to compare these measures by prescription drug source: VA only, Medicare only, or VA and Medicare (dual use). Results: Of 368 891 eligible veterans, 18.3% received prescriptions from the VA only, 30.3% from Medicare only, and 51.4% from both VA and Medicare. The proportion with PQA opioid-benzodiazepine overlap was larger for the dual-use group than the VA-only group (23.1% vs. 17.3%; adjusted risk ratio [aRR], 1.27 [95% CI, 1.24 to 1.30]) and Medicare-only group (23.1% vs. 16.5%; aRR, 1.12 [CI, 1.10 to 1.14]). The proportion with high-dose overlap was also larger for the dual-use group than the VA-only group (4.7% vs. 2.3%; aRR, 2.23 [CI, 2.10 to 2.36]) and Medicare-only group (4.7% vs. 2.9%; aRR, 1.06 [CI, 1.02 to 1.11]). Limitation: Data are from 2013 and cannot capture medications purchased without insurance; unmeasured confounding may remain in this cross-sectional study. Conclusion: Among a national cohort of veterans dually enrolled in VA and Medicare, receiving prescriptions from both sources was associated with greater risk for receiving potentially unsafe overlapping prescriptions for opioids and benzodiazepines. Primary Funding Source: U.S. Department of Veterans Affairs.
Authors: Thomas R Radomski; Xinhua Zhao; Carolyn T Thorpe; Joshua M Thorpe; Jennifer G Naples; Maria K Mor; Chester B Good; Michael J Fine; Walid F Gellad Journal: J Gen Intern Med Date: 2017-05-01 Impact factor: 5.128
Authors: Huanguang Jia; Yu Zheng; Dean M Reker; Diane C Cowper; Samuel S Wu; W Bruce Vogel; Gail C Young; Pamela W Duncan Journal: Stroke Date: 2006-12-28 Impact factor: 7.914
Authors: Walid F Gellad; Joshua M Thorpe; Xinhua Zhao; Carolyn T Thorpe; Florentina E Sileanu; John P Cashy; Jennifer A Hale; Maria K Mor; Thomas R Radomski; Leslie R M Hausmann; Julie M Donohue; Adam J Gordon; Katie J Suda; Kevin T Stroupe; Joseph T Hanlon; Francesca E Cunningham; Chester B Good; Michael J Fine Journal: Am J Public Health Date: 2017-12-21 Impact factor: 9.308
Authors: Kiersten L Strombotne; Aaron Legler; Taeko Minegishi; Jodie A Trafton; Elizabeth M Oliva; Eleanor T Lewis; Pooja Sohoni; Melissa M Garrido; Steven D Pizer; Austin B Frakt Journal: J Gen Intern Med Date: 2022-05-02 Impact factor: 6.473
Authors: Lianlian Lei; Julie Strominger; Ilse R Wiechers; H Myra Kim; Frederic C Blow; Amy S B Bohnert; Lillian Min; Sarah L Krein; Donovan T Maust Journal: J Gen Intern Med Date: 2021-05-28 Impact factor: 6.473